• 제목/요약/키워드: propranolol

검색결과 296건 처리시간 0.03초

Assessment of Double-blindness at the Conclusion of the $\beta-Blocker$ Heart Attack Trial

  • Byington Robert P.;Curb J. David;Mattson Margaret E.
    • 대한예방의학회:학술대회논문집
    • /
    • 대한예방의학회 1994년도 교수 연수회(역학)
    • /
    • pp.293-296
    • /
    • 1994
  • At the conclusion of a double-blinded, randomized clinical trial of propranolol hydrochloride, but before un blinding, the patients and clinic personnel were asked to guess the treatment group assignment of each patient. While 79.9% of the patients receiving propranolol correctly Identified their treatment group assignment, 57.2% of the patients receiving placebo incorrectly guessed that they were aiso in the propranolol group. No specific mechanism was identified to explain why more patients receiving propranolol were better able to guess' their group assignment. Clinic physicians correctly identified the group assignment of 69.9% of the patients receiving propranolol and 68.8% of the patients receiving placebo. Clinic coordinators correctly identified the group assignment of 67.1% of the patients receiving propranolol and 70.6% of the patients receiving placebo. For clinic personnel, heart rate level and heart rate change seem to be the mechanisms employed to Identify their patients' treatment assignment.

  • PDF

Oral propranolol therapy in 23 infants with infantile hemangioma

  • Kim, Jaeyoon;Hong, Jong Won;Roh, Tai Suk;Lee, Won Jai
    • Archives of Plastic Surgery
    • /
    • 제45권6호
    • /
    • pp.517-524
    • /
    • 2018
  • Background Infantile hemangioma (IH) is a common vascular tumor in pediatric patients, and is commonly treated with propranolol. We describe our experiences with dosage, response to treatment, and side effects in 23 IH patients treated with propranolol. Methods For this nonrandomized comparative cohort study, the authors enrolled 23 patients treated with propranolol. Photographs were taken before propranolol administration and at 3, 6, 9, and 12 months after treatment. Treatment responses were objectively analyzed with a computer program. Results There were three male and 20 female patients. Common tumor locations were the head and neck (13 cases, 56.5%), trunk (four cases, 17.4%), extremities (three cases, 13.0%), and combined locations (three cases, 13.0%). The response to propranolol was significantly lower in patients with two or more lesions than in patients with a single lesion in terms of both color fading (P<0.001) and size reduction (P<0.001). In male patients ($42.2{\pm}3.9$), the change in a-values, indicating coloration, was higher than in female patients ($19.8{\pm}13.8$) (P<0.001). In patients who started treatment before 6 months after birth, the size reduction was greater than in their counterparts (62.3%; range, 3.0%-93.0% vs. 15.8%; range, 1.0%-79.0%; P<0.001). Conclusions Propranolol is an efficacious treatment with a good safety profile. In patients with a single lesion, the response to treatment was better in terms of color fading and size reduction. Furthermore, male patients responded better to propranolol treatment in terms of color fading than female patients, and starting treatment before 6 months after birth was more advantageous for size reduction.

A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma

  • Yun, Yeong Ju;Gyon, Yun Hee;Yang, Sohyoung;Lee, Youn Kyung;Park, Joohyun;Park, Meerim
    • Clinical and Experimental Pediatrics
    • /
    • 제58권12호
    • /
    • pp.484-490
    • /
    • 2015
  • Purpose: To determine the efficacy and safety of oral propranolol as a first-line treatment for superficially located infantile hemangioma (IH) and propose an assessment tool to measure treatment response. Methods: Patients with superficial IH under 1 year of age were prospectively recruited between May 2012 and December 2013 at the Department of Pediatrics of Chungbuk National University Hospital. Propranolol was administered to 12 infants (median age, 3.8 months) while monitoring cardiovascular and adverse metabolic effects. If a patient showed no adverse events, the dosage was gradually increased up to 3 mg/kg/day and maintained for 1 year. We used our own scoring system to assess treatment response using parameters like change in color, and longest diameter, and thickness of the IH. Results: Eleven out of 12 patients completed the protocol with consistent improvement of hemangiomas during therapy. Patients on propranolol showed a more than 50% involution in the first 3 months, with additional steady involution until 1 year. Patients with the highest scores at 1 month maintained their score and showed better responses until treatment termination. The patient with the lowest score at 1 month did not show any further regression and stopped propranolol treatment 4 months after initiation. In two children with recurrences after successful therapeutic regression, propranolol was effective after being reintroduced. Propranolol treatment was not interrupted in any patient due to adverse events. Conclusion: Oral propranolol at 3 mg/kg/day showed a consistent, rapid, and therapeutic effect on superficial IHs without significant adverse events.

고양이 유두근의 활동전압에 미치는 d-propranolol의 영향 (EFFECT OF D-PROPRANOLOL ON TRANSMEMBRANE ACTION POTENTIAL OF CARDIAC PAPILLARY MUSCLE OF CAT)

  • 이종흔;김중수
    • 대한치과의사협회지
    • /
    • 제16권7호통권110호
    • /
    • pp.531-536
    • /
    • 1978
  • Adult cats were light anesthetized with ethyl ether and heart was removed fastly. cardiac papillary muscle was dissected from heart in organ bath con taining Tyrode solution saturated with 95% O₂+5% CO₂, and prepared papillary muscles were placed in Tyrode solution that was continuously circulated and gassed with 95% O₂+5% CO₂at 32℃. The isolated papillary muscle was stimulated continuously with platinum pin electrode at frequency of 15/min and 90/min by means of electric stimulator and transmembrane action potentials were recorded with microelectrdes on the oscilloscope. The drug used was d-propranolol and its concentration was 0.5, 1.5 and 5.0 mg/L. The results obtained were as follows: 1. D-propranolol increased the threshold voltage of papillary muscle and raised by average of 213.6% of control. 2. D-propranolol had no effect on duration of action potential. 3. Conduction time of isolated papillary muscle was increased by d-propranolol and its effect was prominent at frequency of 90/min. 4. the maximum upstroke velocity was decreased by d-propranolol and its effect was dose-depndent decrease.

  • PDF

만성 간질환에서 Propranolol의 문맥압 감소 효과: 경직장 문맥 신티그라피를 이용한 평가 (Effect of Propranolol on Portal Vein Pressure in Patients with Chronic Liver Disease: Evaluation by Perrectal Portal Scintigraphy)

  • 노영호;한신;김학수;윤수진;김윤권;김소연;김영중;조민구;박병익;이권전
    • 대한핵의학회지
    • /
    • 제33권4호
    • /
    • pp.388-397
    • /
    • 1999
  • 목적: Propranolol은 비선택적 ${\beta}$ 차단제로 문맥 혈류를 감소시켜 문맥압을 감소시킨다. 이러한 propranolol의 치료에 따른 문맥압 감소 반응정도를 약물투여 전후에 경직장 문맥 신티그라피로 평가하였다. 대상 및 방법: 간경변증 51명과 만성 간염 10명 및 정상 10명을 대상으로 하였고, propranolol 투여의 금기가 없는 38명에서는 propranolol 투여 후 일주일 후 경직장 문맥 신티그라피를 시행하였다. 경직장 문맥 신티그라피는 Tc-99m pertechnetate 370 MBq을 경직장으로 투여한 다음 동적 영상을 얻었고, 30초 동안의 심장과 간의 방사능의 합에 대한 심장의 방사능의 합으로 단락지수를 구하였다. 결과 정상 대조군과 만성 간염 환자군은 모두 pattern I의 유형을 보이고, 간경변증은 10명에서는 pattern 1,40 명에서는 pattern II의 유형을 보였으며, Propranolol 투여 후 맥박수는 투여 전에 비하여 의미 있게 감소하였다. 정상 대조군, 만성 간염, 간경변증으로 나누어 단락지수를 비교한 것은 각각 $5.0{\pm}1.2%$, $11.4{\pm}3.5%$, $59.8{\pm}27.2%$로 정상과 만성 간염 간에는 유의한 차이를 보이지 않았으나, 간경변증은 정상 및 만성 간염에 비하여 유의한 증가를 보였다(p<0.05). 간경변증 환자에서 propranolol 투여 후의 단락지수는 $46.9{\pm}20.9%$로, 투여 전의 단락지수 $55.6{\pm}29.6%$에 비하여 유의한 감소를 보였으나(p<0.05), Child씨 분류법 및 식도 정맥류 정도에 따른 각 군간의 단락지수의 변화정도는 의미 있는 차이가 없었다. 결론: 경직장 문맥 신티그라피를 이용한 단락지수는 간질환의 진행에 따른 문맥압의 정도를 반영하며, Propranolol 투여 후에는 단락 지수가 감소하였다. 경직장 문맥 신티그라피는 비침습적인 방법으로서, 문맥압을 평가하고, propranolol의 효과를 평가할 수 있는 방법으로 유용하게 쓰일 수 있을 것으로 사료된다.

  • PDF

문맥 고혈압 흰쥐에 있어서 내장혈관의 아드레나린성 수용체의 기능변동과 이에 대한 Propranolol의 효과 (Altered Functions of Adrenoceptors in Splanchnic Vascular Beds in Portal Hypertensive Rat Model: Effect of Propranolol)

  • 김치대;홍기환
    • 대한약리학회지
    • /
    • 제24권1호
    • /
    • pp.63-70
    • /
    • 1988
  • 문맥 고혈압 동물에서 내장장기의 혈류역동학적 변동으로서 문맥압의 증가와 동반하여 장간의 혈류량 증가와 혈관저항의 감소뿐만 아니라 전신 혈관저항의 감소가 특징적으로 야기된다. 문맥고혈압에 있어서 propranolol이 beta 1과 beta 2 수용체의 봉쇄작용으로 문맥고혈압을 저하시킨다는 점에서 사용되기도 한다. 본 실험에서는 흰쥐에서 문맥을 부분적으로 결찰하여 문맥고혈압을 야기하고 10일 후에 내장장기의 혈류역동학적 변동과 혈관 수축성 약물에 대한 반응성의 변동을 관찰하였다. 동시에 이에 대한 propranolol의 효과도 검토하였다. 문맥 결찰 후에는 비 펄프압의 증가와 동반하여 내장장기의 혈류량과 모세혈관압 증가가 야기되었고 동시에 모세혈관 전 저항(Ra)과 모세혈관 후 저항(Rv)은 저하되었다. Noradrenaline에 대한 Rv의 증가반응, adrenaline에 대한 Ra와 Rv의 증가반응, 및 phenylephrine에 대한 상장간막 동맥압, Ra및 Rv의 증가반응이 특징적으로 문맥결찰군에서 대조군에 비하여 현저히 약화되었다. Propranolol 처치군(PPL-3)에서 장간막 혈류량의 감소가 초래되었고, 문맥결찰군에서 저하된 Ra와 Rv가 propranolol투여로 대조군 수치로 회복되 었다. 이러한 성적의 결과로 문맥 결찰에 의하여 장간막 혈류량 증가와 동반된 Ra와 Rv의 저하는 비 펄프압 증가로 야기된 것으로 추측되며 내장장기 혈류역동학적 및 혈관 반응도의 변동은 장기적인 propranolol 처치로 효과있게 교정되는 점으로 미루어 내장장기의 과혈류역동은 내장장기 혈관의 아드레나린성 수용체의 기능변동과 밀접한 관련이 있다고 사료되었다.

  • PDF

Atropine, Phentolamine과 Propranolol이 활성화된 다형핵 백혈구에서의 칼슘 흡수, $O_2-$ 생성 및 식작용에 미치는 효과 (Effects of Atropine, Phentolamine and Propranolol on Calcium uptake, Superoxide generation and Phagocytic activity in activated PMN Leukocytes)

  • 이정수;한은숙;이광수
    • 대한약리학회지
    • /
    • 제24권1호
    • /
    • pp.83-92
    • /
    • 1988
  • 세포질 내 칼슘 농도의 증가는 다형핵 백혈구의 산화성 대사를 자극하는 주요 인자로 여겨지고 있다. 활성화된 다형핵 백혈구로부터 lysosomal enzyme의 유리는 세포내 cyclic nucleotide농도에 따라 조절될 수 있지만 신경전달물질과 ${\beta}$-아드레날린 또는 무스카린성 수용체의 결합에 따른 그밖의 반응은 아직도 분명하지 않다. 덧붙여, ${\alpha}$-아드레날린성 수용체의 중개에 의한 다형핵 백혈구의 기능은 알려져 있지 않다. Atropine, phentolamine과 propranolol은 활성화된 다형핵 백혈구의 칼슘흡수, superoxide 생성, NADPH oxidase 활성도 그리고 식작용을 억제하였으며, 이에 반하여 carbachol과 isoproterenol은 활성화된 세포의 반응을 약간 더 자극하였다. Carbachol또는 isoproterenol 의하여 항진된 superoxide 생성은 각각 그들의 길항제인 atropine과 propranolol 의하여 억제되었다. 활성화된 다형핵 백혈구의 반응은 chlorpromazine, verapamil과 dantrolene에 의하여 억제되었으나 lithium에 의 하여 약긴 항진되었다. 한편 chlorpromazine과 dibucaine은 NADPH oxidase 활성도에 영향을 주지 않았다. Atropine, phentolamine과 propranolol은 칼슘에 의존적인 식작용을 억제 하였다. 이상의 결과로부터 atropine, phentolamine과 propranolol은 칼슘 유입을 억제하고 자율 신경계의 수용체와 연관이 있는 NADPH oxidase계에 직접 작용함으로써 활성화된 다형핵 백혈구로부터 superoxide 생성을 억제할 것으로 시사되었다.

  • PDF

푸로푸라놀롤과 안지오텐신 차단제와의 체내 상호작용 (Pharmacokinetic Interaction of Propranolol and Angiotensin Inhibitor in Rabbits)

  • 최준식;이진환;범진필
    • Journal of Pharmaceutical Investigation
    • /
    • 제20권1호
    • /
    • pp.1-5
    • /
    • 1990
  • Effect of an angiotensin inhibitor (AAS; loading dose of 25, 50, $100{\mu}g/kg$ and maintenance dose of 12.5, 25,$50{\mu}g/ka/hr$) on the pharmacokinetics of propranolol (4 mg/kg i.v.) was studied in rabbits. Plasma concentrations and relative bioavailability of propranolal increased upto 127-175% by AAS coinjection. The urinary excretion of propranolol decreased by AAS. Dosage regimen of propranolol should be adjusted when it is administered with AAS.

  • PDF

Cinnarizine을 Propranolol이나 Metoprolol과 병용할 때의 혈압(血壓) 강하(降下) 효과(效果)에 관한 약리학적(藥理學的) 연구(硏究)(I) -혈압(血壓) 변화(變化)에 대한 효과- (Pharmacological Studies on the Antihypertensive Effects of Cinnarizine Coadministered with Propranolol or Metoprolol(I) -Effects on Blood Pressure Change-)

  • 허인회;안형수
    • 약학회지
    • /
    • 제28권5호
    • /
    • pp.249-256
    • /
    • 1984
  • The effects of $Ca^{2+}-antagonist$, cinnarizine, on the antihypertensive effects of propranolol and metoprolol were investigated in normal cat (i. v.) and SHR (p. o.). Cinnarizine increased the antihypertensive effect of propranolol, but not of metoprolol. It inhibited the heart rate decreasing effects of propranolol and metoprolol slightly. It decreased the norepinephrine-induced blood pressure increasing effect and isoproterenol-induced blood pressure decreasing effect when coadministered with metoprolol orally for 4 weeks in SHRs.

  • PDF

Propranolol.HCl의 Cellulose Acetate Phthalate Microencapsulation에 관한 연구 (Microencapsulation of Propranolol.HCl with Cellulose Acetate Phthalate)

  • 구영순;김재연
    • 약학회지
    • /
    • 제33권5호
    • /
    • pp.312-318
    • /
    • 1989
  • Microcapsule of Propranolol HCl with Cellulose Acetate Phthalate (CAP) by coacervation-phase separation method was studied. Encapsulation was carried out in the CAP-liquid paraffin-acetone ethanol solvent system. The optimum weight ratio for microencapsulation in the CAP-liquid paraffin-solvent system was 1.32:89.18:9.50 or 1.65:89.42:8.93. The wall thickness of microcapsules increased according to increasing of CAP concentration, but dissolution rate decreased. The dissolution of propranolol-HCl in simulated gastric and intestinal fluid test solution was completed within 3 min., but T50% of propranolol HCl from 10.0% CAP-microcapsules were 390 min. and 210 min. respectively. The released amount from 12.5% CAP-microcapsules was 41.8% within 720 min. in simulatd gastric fluid test solution and T50% of those in simulated intestinal fluid test solution was 250 min.

  • PDF